Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5th PLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a...

Sustainable Innovation Fuels Corteva's Pipeline, Creating Value Now and for Decades to Come INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) will host a virtual R&D...

Compliance acts as primary driver for obtaining cyber insurance, but budget constraints hinder efforts SAN FRANCISCO, April 27, 2023 /PRNewswire/ -- Delinea, a leading provider of solutions that...

- Poster data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease - Consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety...

Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor...